CJ Bioscience Accelerates Microbiome Commercialization... Targeting the Personalized Wellness Market
Three Poster Presentations and Two Session Talks Delivered at IHMC 2026
On June 5, CJ Bioscience announced that it had participated in the International Human Microbiome Consortium (IHMC 2026), a globally prestigious microbiome academic conference, where it unveiled its microbiome R&D platform and innovative new drug pipeline research achievements. The company, which is currently pursuing expansion into the health and wellness business, showcased three poster presentations and two in-depth session presentations at the conference, introducing its gut microbiome simulation and AI platform technologies that are expected to become the driving force for its future wellness business.
The research achievements presented by CJ Bioscience at this conference were based on a wide range of microbiome analysis technologies that the company has accumulated over time. The results demonstrated that the company is expanding its differentiated research and development capabilities not only in new drug development but also in the wellness sector, earning high praise from both academia and industry.
CJ Bioscience participated in the internationally renowned microbiome academic conference, the International Human Microbiome Consortium (IHMC 2026), where it unveiled its microbiome R&D platform and innovative new drug pipeline research achievements. CJ Bioscience
View original imageAt the luncheon session held on June 3, Professor Oh Beomjo from the Department of Family Medicine at Seoul National University Boramae Medical Center delivered a presentation on the results of a large-scale human intervention study for a complex Microbiota-Accessible Carbohydrate (MAC) formula developed using CJ Bioscience’s high-throughput screening platform, the "Human Gut Ecosystem Simulation System." By applying four types of MAC formulas designed on the company's proprietary gut simulation platform to 210 adults, the study established scientific evidence supporting personalized intake based on individual gut types. In particular, the high similarity between laboratory simulations and actual clinical results demonstrated the utility of the company’s proprietary gut simulation system.
Furthermore, the company developed an AI model capable of predicting product responders with high accuracy (ROC-AUC 0.85) based on individual gut microbiome patterns, suggesting the potential for more sophisticated personalized dietary recommendations. Leveraging these core technological capabilities, the company plans to initiate human trials in the fourth quarter of this year to prevent “weight regain after weight loss,” a representative side effect of obesity treatments such as GLP-1 agonists.
At the industry session on the same day, CJ Bioscience unveiled the unique anti-inflammatory therapeutic mechanism and efficacy data of its key new drug pipeline candidate, "CJRB-201." The company is focusing on inflammatory bowel disease (IBD), which is closely associated with pathological gut microbiota. CJRB-201 is a substance developed based on beneficial bacteria uniquely found in the gut of healthy individuals, as opposed to those of IBD patients. The research confirmed that when CJRB-201 stably colonizes the gut, effective metabolites including the representative anti-inflammatory compound butyrate are secreted, which can improve intestinal barrier damage, a major cause of IBD. In a chronic colitis mouse model, application of CJRB-201 produced anti-inflammatory effects, as well as protection against weight loss and suppression of inflammatory cytokines at a level comparable to global antibody therapeutics, confirming its potential as an innovative new drug.
Meanwhile, CJ Bioscience also presented research findings regarding the "Microbiome-Friendly Diet Score," which predicts the correlation between gut microbiota and dietary patterns by combining large-scale human microbiome and dietary clinical data. Analysis of real data from 543 Koreans confirmed the correlation between uniquely Korean food ingredients and changes in gut microbiome patterns, demonstrating superior predictive power over existing systems and proving its core technological strength for future personalized diet recommendations. In addition, by verifying the correlation with biomarkers such as blood glucose and inflammation using large-scale data from the National Health and Nutrition Examination Survey conducted by the Korea Disease Control and Prevention Agency, the reliability of the research was further enhanced.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
A representative from CJ Bioscience stated, "This conference presentation is proof that our microbiome R&D platform technology is competitive not only in new drug development but also in various wellness fields," adding, "Based on our proprietary microbial research platform technologies, we will accelerate the development of innovative new microbiome drugs and, at the same time, advance the commercialization of personalized precision nutrition solutions, ultimately transforming the healthcare market paradigm." The representative continued, "Based on the results of this MAC human intervention study, we plan to commercialize and launch a personalized MAC solution in the market during the second half of this year."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.